Pacira reports Q4 EXPAREL net product sales $147.7M vs. $143.9M last year

Fourth quarter EXPAREL net product sales of $147.7 million in 2024, compared with $143.9 million in 2023. Volume growth and a price increase in 2024 were partially offset by a shift in vial mix and discounting associated with the company’s new group purchasing organization, or GPO, partnerships. Fourth quarter ZILRETTA net product sales of $33.1 million in 2024, compared with $28.7 million in 2023. Fourth quarter iovera degrees net product sales of $6.5 million in 2024, compared with $6.0 million in 2023. Other revenue, including sales of bupivacaine liposome injectable suspension and royalties, was zero in the fourth quarter of 2024, compared with $2.6 million in the fourth quarter of 2023.